Effect of subanesthetic dose esketamine on anxiety and depression in patients with breast cancer after surgery: a randomized controlled, double-blind study - Takeaways - MDSpire

Effect of subanesthetic dose esketamine on anxiety and depression in patients with breast cancer after surgery: a randomized controlled, double-blind study

  • By

  • Song-Yuan Liu

  • Rong Huang

  • Zhuang Liu

  • Shou-Shi Wang

  • Ming-Qiang Zhao

  • February 9, 2026

  • 0 min

Share

  • 1

    Breast cancer significantly impacts women's mental health, leading to increased anxiety and depression during the perioperative phase.

  • 2

    Esketamine, an NMDA receptor antagonist, shows potential for rapid management of anxiety and depression in post-surgical breast cancer patients.

  • 3

    The study involved 120 breast cancer patients, randomly assigned to receive either esketamine or a saline placebo during surgery.

  • 4

    Primary outcomes included PHQ-9 scores at postoperative day 30, assessing the sustained antidepressant effects of esketamine.

  • 5

    The trial was conducted in a double-blind manner, ensuring unbiased administration and assessment of esketamine's effects.

Original Source(s)

Effect of subanesthetic dose esketamine on anxiety and depression in patients with breast cancer after surgery: a randomized controlled, double-blind study

  • by Song-Yuan Liu, Rong Huang, Zhuang Liu, Shou-Shi Wang, Ming-Qiang Zhao

  • February 9, 2026

Related Content

Auricular acupuncture for insomnia in female patients with non-metastatic breast cancer: study protocol for a multicenter, randomized, controlled clinical trial

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Identifying key predictors of post-stroke depression and cognitive impairment in acute stroke survivors